Germline predisposition in myeloproliferative neoplasms

Seminars in Hematology · Published 2026-07-01 · DOI 10.1053/j.seminhematol.2026.06.006

Authors (2)

Meytal Chernoff, Michael W. Drazer

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Chernoff, M., Drazer, M. (2026). Germline predisposition in myeloproliferative neoplasms. Seminars in Hematology. https://doi.org/10.1053/j.seminhematol.2026.06.006

Related articles

• Menin inhibition for the treatment of acute leukemia · Seminars in Hematology · 2025 · Same journal
• Closing the Disease Modification Gap: Emerging Therapies in Myelofibrosis Beyond JAK Inhibition · Seminars in Hematology · 2026 · Same journal
• outside front cover, PMS 8883 metallic AND 4/C · Seminars in Hematology · 2025 · Same journal
• Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics · Seminars in Hematology · 2025 · Same journal
• Harnessing single-domain antibodies for CAR-T and bispecific antibody development · Seminars in Hematology · 2025 · Same journal
• Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis · Seminars in Hematology · 2026 · Same journal
• Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications · Seminars in Hematology · 2025 · Same journal
• The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology · Seminars in Hematology · 2025 · Same journal
• Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions · Seminars in Hematology · 2026 · Same journal
• Repositioning neutrophils in cancer immunotherapy: From innate defenders to antibody-driven effectors · Seminars in Hematology · 2025 · Same journal